+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter randomized phase III study evaluating epirubicin-cyclophosphamide versus epirubicin-docetaxel for first-line treatment of metastatic breast cancer Good tolerability and efficacy of epirubicin-docetaxel in heavily pretreated patients with high tumor load



Multicenter randomized phase III study evaluating epirubicin-cyclophosphamide versus epirubicin-docetaxel for first-line treatment of metastatic breast cancer Good tolerability and efficacy of epirubicin-docetaxel in heavily pretreated patients with high tumor load



Breast Cancer Research & Treatment 82(Supplement 1): S128




(PDF emailed within 1 workday: $29.90)

Accession: 035349908

Download citation: RISBibTeXText


Related references

Multicenter randomized phase III study evaluating epirubicin/cyclophosphamide versus epirubicin/docetaxel for first line treatment of metastatic breast cancer An interim analysis of safety and efficacy. Breast Cancer Research & Treatment 76(Supplement 1): S90, 2002

Epirubicin/docetaxel versus 5FU/epirubicin/cyclophosphamide combinations as first line chemotherapy in patients with metastatic breast cancer. Breast Cancer Research & Treatment 69(3): 215, 2001

Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. Annals of Oncology 21(7): 1430-1435, 2010

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology 18(1): 52-57, 2006

Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first-line treatment of metastatic breast cancer A study of the AGO breast cancer study group. Seminars in Oncology 26(6 Suppl 18): 8, 1999

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. British Journal of Cancer 91(8): 1466-1471, 2004

A randomized multicenter phase III trial comparing epirubicin and paclitaxel with epirubicin and cyclophosphamide as first line chemotherapy in patients with metastatic breast cancer. Breast Cancer Research & Treatment 57(1): 84, 1999

Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC). Journal of Clinical Oncology 23(16_suppl): 707-707, 2016

Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study. Tumori 92(1): 6-12, 2006

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. Journal of Clinical Oncology 33(32): 3788-3795, 2016

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. Journal of Clinical Oncology 23(7): 1401-1408, 2005

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. Journal of Clinical Oncology 29(24): 3247-3254, 2011

Randomized trial of first-line docetaxel + capecitabine (XT) versus docetaxel + epirubicin (ET) for metastatic breast cancer (MBC): Efficacy results of ERASME-4/CAPEDOC-EPIDOC. Journal of Clinical Oncology 26(15_suppl): 1049-1049, 2016

6 cycles of Epirubicin /Taxotere versus 6 cycles of 5FU/Epirubicin /Cyclophosphamide as first line metastatic breast cancer treatment Preliminary results of a randomized phase II trial. Breast Cancer Research & Treatment 64(1): 79, 2000

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Annals of Oncology 21(1): 48-54, 2010